Barrington Lowers PT on OPKO Health (OPK), Keeps a Buy

Core Insights - OPKO Health, Inc. (NASDAQ:OPK) has seen a price target reduction from $2.25 to $1.50 by Barrington, while maintaining a Buy rating, indicating concerns over the sustainability of its revenue performance despite beating Street estimates for fiscal Q4 2025 [1][3] Financial Performance - For fiscal Q4 2025, OPKO reported a revenue decline of 19.12% year-over-year to $148.5 million, although it exceeded consensus estimates by $8.74 million [3] - The earnings per share (EPS) was negative $0.04, surpassing expectations by $0.03 [3] Revenue Breakdown - Diagnostic revenue for the quarter was $71.1 million, down from $103.1 million a year ago, primarily due to the sale of BioReference assets and a decline in clinical test volumes, partially offset by increased demand for the 4Kscore test [4] Future Outlook - OPKO expects fiscal Q1 2026 revenue to be between $125 million and $140 million, with full-year revenue projected in the range of $530 million to $560 million [5] Company Overview - OPKO Health, Inc. operates in the biopharmaceutical and diagnostics sectors, developing treatments such as NGENLA and Rayaldee, targeting markets in the US and Latin America [6]